Literature DB >> 3105939

Plasma interleukin 2 receptor levels in renal allograft recipients.

R B Colvin, T C Fuller, L MacKeen, P C Kung, S H Ip, A B Cosimi.   

Abstract

Shed/soluble interleukin 2 receptor (IL2R) was measured by an enzyme-linked immunosorbent assay (ELISA) in serial samples of plasma from 32 patients with renal allografts. Patients on chronic dialysis (pretransplant) had elevated IL2R levels which fell toward normal after transplantation. Patients with acute rejection and viral infection had significantly higher levels of plasma IL2R than did patients with stable renal function or with cyclosporine nephrotoxicity (all P less than 0.005). Acute renal failure from other causes (renal artery stenosis, hemolytic-uremic syndrome) did not have a comparable rise in IL2R. The assay of shed/soluble IL2R may have diagnostic value in the clinical management of allograft recipients, a possibility that deserves further clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105939     DOI: 10.1016/0090-1229(87)90135-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  25 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency.

Authors:  M E North; G P Spickett; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

4.  Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.

Authors:  Z Toossi; J R Sedor; J P Lapurga; R J Ondash; J J Ellner
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Serum interleukin-2-receptor in coeliac disease: response to treatment and gluten challenge.

Authors:  J E Crabtree; R V Heatley; L D Juby; P D Howdle; M S Losowsky
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

6.  Monoclonal antibodies for clinical applications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1988-12       Impact factor: 2.926

7.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

8.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

9.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria.

Authors:  P Deloron; J P Lepers; P Coulanges
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.